| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
TARA Stock Overview
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases.
Protara Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.66 |
| 52 Week High | US$7.16 |
| 52 Week Low | US$2.38 |
| Beta | 1.44 |
| 1 Month Change | 28.87% |
| 3 Month Change | 13.31% |
| 1 Year Change | -41.81% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -87.80% |
Recent News & Updates
The Prognosis For Protara Therapeutics
Oct 13Here's Why We're Not Too Worried About Protara Therapeutics' (NASDAQ:TARA) Cash Burn Situation
Sep 12
Recent updates
Here's Why We're Not Too Worried About Protara Therapeutics' (NASDAQ:TARA) Cash Burn Situation
Sep 12Will Protara Therapeutics (NASDAQ:TARA) Spend Its Cash Wisely?
Mar 21Is Protara Therapeutics (NASDAQ:TARA) In A Good Position To Deliver On Growth Plans?
Dec 06Will Protara Therapeutics (NASDAQ:TARA) Spend Its Cash Wisely?
Aug 17What Type Of Shareholders Make Up Protara Therapeutics, Inc.'s (NASDAQ:TARA) Share Registry?
Mar 08How Many Protara Therapeutics, Inc. (NASDAQ:TARA) Shares Have Insiders Sold, In The Last Year?
Jan 12
Shareholder Returns
| TARA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 1.1% | 4.2% | 1.5% |
| 1Y | -41.8% | -7.4% | -14.9% |
Return vs Industry: TARA underperformed the US Biotechs industry which returned -7.4% over the past year.
Return vs Market: TARA underperformed the US Market which returned -14.9% over the past year.
Price Volatility
| TARA volatility | |
|---|---|
| TARA Average Weekly Movement | 11.2% |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 7.4% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: TARA is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: TARA's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 31 | Jesse Shefferman | https://www.protaratx.com |
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company’s lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease.
Protara Therapeutics, Inc. Fundamentals Summary
| TARA fundamental statistics | |
|---|---|
| Market Cap | US$41.24m |
| Earnings (TTM) | -US$37.21m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.1x
P/E RatioIs TARA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TARA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$37.21m |
| Earnings | -US$37.21m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.30 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did TARA perform over the long term?
See historical performance and comparison